Emerging Microbes & Infections is a premier open access journal, published by Taylor & Francis Ltd since 2012, dedicated to advancing the understanding of microbial infections and their implications in human health. With an impressive Q1 ranking across multiple categories—including Drug Discovery, Epidemiology, Immunology, and Infectious Diseases—this journal is at the forefront of research in the microbiological sciences. Covering a diverse range of topics, it serves as a vital resource for researchers, healthcare professionals, and students alike. The journal's commitment to open access ensures worldwide dissemination of cutting-edge findings, fostering collaboration and innovation in tackling challenges posed by emerging infections. As part of the thriving academic community in the United Kingdom, Emerging Microbes & Infections plays a crucial role in shaping the future of infectious disease research and public health.

REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO is a prestigious open-access journal that has been publishing significant research in the field of tropical medicine since its inception in 1961. Produced by the Instituto de Medicina Tropical de São Paulo, the journal boasts a commendable Q3 ranking in both the categories of Infectious Diseases and Medicine (miscellaneous), as per the latest 2023 metrics. With an ISSN of 0036-4665 and E-ISSN of 1678-9946, it serves as a prominent platform for scholars and professionals to disseminate their findings and insights on pressing health issues prevalent in tropical regions, particularly those relevant to Brazil and beyond. This journal is essential for researchers and practitioners who seek to advance their understanding and apply innovative solutions in tropical medicine, thus addressing the distinct challenges posed by infectious diseases in diverse populations. The journal is accessible through various open access platforms, ensuring that critical research is available to a global audience, fostering knowledge sharing and collaboration.

Vaccines, published by MDPI in Switzerland, is a leading open access journal that has been at the forefront of vaccine research since its inception in 2013. With an impressive impact factor and consistently ranked in the Q1 and Q2 quartiles across leading categories such as Drug Discovery, Immunology, Infectious Diseases, and Pharmacology, it provides a vital platform for researchers to share their findings and advance the field. The journal is dedicated to delivering high-quality original research articles, reviews, and case studies that address the challenges and innovations in vaccine development and immunization strategies worldwide. Open access since its launch, Vaccines ensures that cutting-edge research is widely available to the global academic community and public health professionals, thereby fostering collaboration and enhancing knowledge in this critical area of public health.

The JOURNAL OF INFECTIOUS DISEASES, published by OXFORD UNIV PRESS INC, is a leading peer-reviewed journal dedicated to advancing the understanding of infectious diseases through high-quality research. With an impressive impact factor reflecting its prominence in the field—ranking in the Q1 category for both Immunology and Allergy and Infectious Diseases—this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike. Its extensive history, spanning over a century since its inception in 1904, highlights its established authority and commitment to the field. Based in the United Kingdom, the journal covers essential topics from clinical management to epidemiological trends, providing vital insights that inform practice and policy. Although the journal is not open access, it remains accessible to a wide audience, ensuring that critical research continues to drive innovation and best practices in infectious disease management.

Vaccine is a premier academic journal published by Elsevier Science Ltd, dedicated to the field of vaccination and immunization research. With an impact factor and H-index that underscore its significance in the scientific community, this journal has consistently ranked in the Q1 category within various fields, including Immunology and Microbiology, Infectious Diseases, and Public Health. Since its inception in 1983, it has served as a vital resource for researchers, healthcare professionals, and students, providing rigorous peer-reviewed articles that explore important breakthroughs and innovations in vaccine development and deployment. Although it does not operate under an Open Access model, the journal maintains high visibility within academic circles, thanks to its strategic collaborations and widely respected editorial board. By bridging the gaps between laboratory discoveries and clinical applications, Vaccine plays a crucial role in advancing global health initiatives and addressing urgent public health challenges.

Open Forum Infectious Diseases (ISSN: 2328-8957; E-ISSN: 2328-8957) is a leading open-access journal published by Oxford University Press, dedicated to advancing the field of infectious diseases. Since its inception in 2014, the journal has provided a platform for researchers to disseminate impactful findings in a rapidly evolving domain, achieving a remarkable Q1 ranking in both the Infectious Diseases and Oncology categories as of 2023. The journal encourages rigorous and innovative research, contributing significantly to global health discussions and informing best practices in clinical settings. As an open-access journal, it ensures that its content is accessible to a wide audience, fostering collaboration and knowledge sharing among researchers, professionals, and students alike. Positioned in the heart of the United States, Open Forum Infectious Diseases serves as a critical resource for the academic community, and its continued commitment to quality and relevance secures its status as an essential publication in the field.

Future Science OA is an esteemed open-access journal published by FUTURE SCI LTD, dedicated to advancing knowledge in the fields of biotechnology and medicine. Established in 2015, this journal has rapidly gained recognition within the scientific community, evidenced by its impressive ranking in both General Medicine (Rank #100/636, 84th percentile) and Biotechnology (Rank #145/311, 53rd percentile) as per Scopus metrics. With a Q2 category quartile in both fields as of 2023, Future Science OA provides a vital platform for researchers, professionals, and students to share groundbreaking research and innovative ideas. Notably, being an open-access journal allows for a wider dissemination of knowledge, ensuring equal access to high-quality research for practitioners and scholars alike. Based in the United Kingdom, Future Science OA is committed to fostering collaboration and dialogue within the scientific community, making it a cornerstone resource for advancing the future of the life sciences.

Welcome to the Journal of Virus Eradication, a premier publication dedicated to advancing the field of virology and infectious disease research. Published by MEDISCRIPT LTD, this journal provides a vital platform for sharing cutting-edge research findings in key areas including epidemiology, immunology, and public health. With an impressive classification of Q2 in Epidemiology and Infectious Diseases for 2023, this journal exemplifies a commitment to high-quality scholarship and impactful research. The Journal of Virus Eradication is instrumental in disseminating knowledge that tackles viral threats, contributing to global health initiatives aimed at virus containment and eradication. Researchers, professionals, and students alike will find this journal an invaluable resource, making significant contributions to the scientific community and society at large.

Viral Immunology, published by Mary Ann Liebert, Inc, stands as a prominent journal dedicated to advancing the understanding of the interplay between viral infections and host immune responses. With a strong focus on immunology, molecular medicine, and virology, the journal provides a platform for the dissemination of high-quality research findings and innovative methodologies that could shape the future of these critical fields. Although it currently holds a Q3 rating across its relevant categories and a respectable ranking within the Scopus database, Viral Immunology continues to strive for excellence with a commitment to publishing influential research that informs both academic and clinical practices. The journal accepts submissions in various formats—original research, reviews, and commentaries—catering to a diverse readership that includes researchers, professionals, and students engaged in the biological and medical sciences. Readers can anticipate insightful articles that address urgent challenges in immunological responses to viral infections, paving the way for new therapeutic strategies and public health initiatives.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, published by ELSEVIER SCI LTD, stands as a leading platform in the realm of infectious diseases, contributing significantly to the global understanding of this critical field. With an impressive impact factor, the journal maintains a distinguished Q1 ranking across various categories, including Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, demonstrating its high relevance and influence among contemporary research. Since its inception in 1996, it has embraced an Open Access model, allowing for wider dissemination of essential research findings that can inform public health policies and clinical practices. With a commitment to advancing scientific knowledge, this journal is not only a vital resource for researchers and professionals but also serves as an invaluable educational tool for students interested in the complexities of infectious diseases and their management. For those looking to stay at the forefront of research and innovation in this field, the INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES is an indispensable resource.